When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Foodborne E coli infection

Последний просмотренный: 5 Apr 2026
Last updated: 23 Apr 2026

Резюме

Definition

Anamnesis y examen

Principales factores de diagnóstico

  • diarrhea
  • history of travel, contact with contaminated food, or contact with infected person
Todos los datos

Otros factores de diagnóstico

  • abdominal pain or discomfort
  • volume depletion
  • fever
  • nausea/vomiting
  • anorexia
  • lethargy
Todos los datos

Factores de riesgo

  • ingestion of contaminated food products or water
  • travel
  • poor hygiene practices
  • infantile or advanced age (<5 years and >65 years)
  • contact history
  • immunocompromised state
  • contact with infected animals
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • stool cultures
  • CBC
  • renal function and electrolytes
Todos los datos

Pruebas diagnósticas que deben considerarse

  • identification of Shiga toxin-producing E coli infection
  • blood cultures
  • inflammatory markers (CRP and/or erythrocyte sedimentation rate)
  • abdominal x-ray
  • endoscopy
  • abdominal CT scan
Todos los datos

Algoritmo de tratamiento

Inicial

suspected foodborne illness

Agudo

confirmed enterotoxigenic positive

confirmed enterohemorrhagic positive

other Escherichia coli serotypes

Colaboradores

Autores

Eli D. Ehrenpreis, MD, FACG, AGAF

Reaserch Director

Internal Medicine Residency

Advocate Lutheran General Hospital

Park Ridge

IL

Professor of Medicine

Wake Forest University Medical School

Winston-Salem

NC

Divulgaciones

EDE is CEO, owner, and shareholder for E2Bio Life Sciences LLC. E2Bio Life Sciences LLC has developed Bocaliner, an FDA-registered class 1 medical device designed to enhance the efficacy of topical medications applied to the oral cavity. EDE is the inventor and owner of patents for this device. EDE is also a CEO of G.I. Pharmaceuticals Inc., which has medical treatments for oral leukoplakia designed to prevent oral cancer, and a new medication for anal pruritus. G.I. Pharmaceuticals Inc. is involved with the development of educational programs for students and medical trainees.

Agradecimientos

Dr Eli D. Ehrenpreis would like to gratefully acknowledge the assistance of Dr Olivia Foy, who contributed to this update. Dr Eli D. Ehrenpreis would like to gratefully acknowledge Dr Olivia Foy, Dr Alexandra Kent, and the late Professor Satish Keshav, the previous contributors to this topic.

Divulgaciones

OF and AK declare that they have no competing interests.

Revisores por pares

Andrew Poullis, BSc, MBBS, MD, FRCP

Consultant Gastroenterologist

St George’s Hospital

London

UK

Divulgaciones

AP declares that he has no competing interests.

Fiona Cooke, MA, PhD, MSc, FRCPath, MRCP, DTM&H

Research Fellow and Medical Microbiologist

Wellcome Trust Sanger Institute

Department of Microbiology

Addenbrooke's Hospital

Cambridge

UK

Divulgaciones

FC declares that she has no competing interests.

Houssam E. Mardini, MD, MPH, FACP

Voluntary Assistant Professor of Medicine

Digestive Health & Nutrition Center of Ashland

Ashland

KY

Divulgaciones

HEM declares that he has no competing interests.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-80.Texto completo  Resumen

Centers for Disease Control and Prevention. CDC Yellow Book 2026: health information for international travel: preparing international travelers - travelers' diarrhea. 2025 [internet publication].Texto completo

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Diferenciales

    • Viral gastroenteritis
    • Alternative foodborne bacterial gastroenteritis/traveler's diarrhea
    • Amebiasis
    Más Diferenciales
  • Guías de práctica clínica

    • E. coli (Escherichia coli) infection
    • Infectious diarrhea - guideline for investigation
    Más Guías de práctica clínica
  • Folletos para el paciente

    Diarrhea in adults

    Diarrhea in children

    Más Folletos para el paciente
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad